Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects.

Abstract

Dementia is considered a clinical syndrome characterized by cognitive dysfunction and memory loss. Alzheimer's disease (AD) is the most common type of dementia. AD is linked with the turbulence of diverse neurotransmitters including gamma-aminobutyric acid (GABA). Notably, GABA in the brain and cerebrospinal fluid was reduced in AD. Thus, allosteric modulation of the GABA effect by benzodiazepines (BDZs) may improve the clinical outcomes of AD patients. Therefore, the objective of the present review was to reveal the possible role of BDZs on the pathogenesis and clinical outcomes in AD patients. Though BDZs may adversely affect cognitive functions mainly in elderly patients, herein it was postulated that BDZs may have beneficial, neutral, or detrimental effects in AD. Taken together, there is strong controversy regarding the use of BDZs and the risk for the development of AD. Therefore, experimental, preclinical and clinical studies are critical to determine the potential protective or detrimental effects of BDZs on AD neuropathology.

• Authors: Hayder M Al-Kuraishy, Ali I Al-Gareeb, Hebatallah M Saad, Gaber El-Saber Batiha
• Journal: Inflammopharmacology (Inflammopharmacology) Vol. 31 Issue 1 Pg. 221-230 (Feb 2023) ISSN: 1568-5608 [Electronic] Switzerland
• PMID: 36418599 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Benzodiazepines
• gamma-Aminobutyric Acid

Topics

• Humans
• Aged
• Benzodiazepines (pharmacology)
• Alzheimer Disease (pathology)
• gamma-Aminobutyric Acid
• Brain
• Cognition